What we know—and still need to learn—about CBC therapies
Cannabichromene (CBC): a comprehensive review of biosynthesis, pharmacology, therapeutic potential, and translational perspectives.
AI Summary
Cannabis sativa produces over 150 phytocannabinoids, but cannabichromene (CBC) remains much less studied than THC, CBD, and CBG. The review describes CBC as non-intoxicating and explains how it is produced, extracted, analyzed, absorbed, metabolized, and eliminated. CBC appears to interact only minimally with CB1 and CB2 receptors, while acting more strongly on TRP channels involved in sensory signaling and potentially influencing the body’s endocannabinoid activity by reducing anandamide reuptake.
Preclinical research suggests possible anti-inflammatory, analgesic, antimicrobial, anticancer, neuroprotective, antidepressant, and dermatological effects. However, the abstract reports no clinical trials, and it highlights CBC’s notably low oral bioavailability, possible drug-interaction concerns, formulation difficulties, and fragmented regulation. For cannabis users, this means CBC is an intriguing non-intoxicating compound—not a clinically established treatment. The review concludes that CBC is a high-potential but critically understudied cannabinoid requiring better delivery systems and rigorous human research.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Pain research papers you might find interesting.
Interviews explore how adults with regular pain perceive cannabis use
An 18-month cohort found adverse outcomes were infrequent, but long-term risks…
Language models can extract documented cannabis use, but need validation
Explore More Research
Stay informed about the latest cannabis science.